What is HC Wainwright's Forecast for CGTX FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS forecast to a loss of $0.18 per share from $0.20 and maintained its Buy rating; the broader consensus estimate is a $0.22 loss.
• Cognition Therapeutics reported a quarterly loss of $0.04 per share, beating analysts’ $0.07-loss consensus by $0.03.
• Analyst sentiment is mixed but leans positive: the stock has a “Moderate Buy” consensus rating and a $3.33 average price target, though shares at $0.67 were below their 50-day and 200-day moving averages.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Stock analysts at HC Wainwright boosted their FY2026 EPS estimates for Cognition Therapeutics in a research report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.18) for the year, up from their previous forecast of ($0.20). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Cognition Therapeutics' Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen cut Cognition Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $3.33.

Cognition Therapeutics Stock Performance

CGTX opened at $0.67 on Wednesday. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.81. The business has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $1.04.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Cognition Therapeutics in the 2nd quarter worth approximately $1,451,000. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the second quarter worth approximately $369,000. Renaissance Technologies LLC increased its holdings in shares of Cognition Therapeutics by 15.2% in the first quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company's stock valued at $848,000 after buying an additional 147,623 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cognition Therapeutics in the second quarter valued at $165,000. Finally, Sigma Planning Corp lifted its position in shares of Cognition Therapeutics by 56.3% during the 1st quarter. Sigma Planning Corp now owns 337,765 shares of the company's stock valued at $257,000 after acquiring an additional 121,600 shares during the last quarter. Institutional investors and hedge funds own 43.35% of the company's stock.

More Cognition Therapeutics News

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings forecasts, narrowing its projected annual loss to $0.18 per share from $0.20 and $0.19, respectively. It also improved several quarterly estimates to a loss of $0.04 per share from $0.05 and maintained its Buy rating.
• Positive Sentiment: Cognition Therapeutics was upgraded to Zacks Rank #2 (Buy), reflecting improving earnings expectations and potentially bolstering near-term sentiment. Article: What Makes Cognition Therapeutics (CGTX) a New Buy Stock
• Neutral Sentiment: CEO Lisa Ricciardi plans to attend the Jefferies Global Healthcare Conference on November 16–19 and discuss the company’s recent FDA meeting on endpoints for a planned Phase 3 zervimesine study in dementia with Lewy bodies. No new FDA decision or trial outcome was announced. Article: Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
• Neutral Sentiment: A short-interest report described a large increase but listed total short interest as zero shares, making the figures inconsistent and difficult to interpret.
• Negative Sentiment: At the provided $0.67 reference price, CGTX remains below its 50-day ($0.87) and 200-day ($1.04) moving averages, indicating a weaker recent technical trend despite the positive analyst revisions.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration. Cognition Therapeutics' lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.